Ulcerative colitis

Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT2206, a Stelara® Biosimilar

Friday, October 15, 2021 - 1:08pm

Bio-Thera and Pharmaparks partnership was initiated around a licensing and supply agreement for Pharmapark to distribute and market BAT2506, a golimumab biosimilar, in Russia and other CIS countries.

Key Points: 
  • Bio-Thera and Pharmaparks partnership was initiated around a licensing and supply agreement for Pharmapark to distribute and market BAT2506, a golimumab biosimilar, in Russia and other CIS countries.
  • Pharmapark will be responsible for filing the dossier in Russia and other CIS countries.
  • This partnership will leverage Pharmaparks strong local presence, sales and marketing capabilities in Russia and other CIS countries.
  • Bio-Thera is pleased to expand our partnership with Pharmapark to commercialize our ustekinumab biosimilar program in Russia and other CIS countries, said Dr. Shengfeng Li, CEO of Bio-Thera.

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Thursday, October 14, 2021 - 2:00pm

The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.

Key Points: 
  • The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.
  • Patient screening is underway at clinical trial sites in Italy and will start soon in Austria and Germany.
  • First Wave BioPharma is also planning a separate clinical trial to investigate an oral formulation of niclosamide as a potential treatment for pancolitis.
  • FW-UP is a niclosamide-based, small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS).

Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline

Thursday, October 14, 2021 - 12:00pm

Short-term pain management has its own considerable challenges, not the least being a continued reliance on opioids, for which otenaproxesul is an ideal fit.

Key Points: 
  • Short-term pain management has its own considerable challenges, not the least being a continued reliance on opioids, for which otenaproxesul is an ideal fit.
  • In collaboration with outside experts and key opinion leaders, the Company has completed a comprehensive assessment of the AME study data.
  • Antibes lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for acute pain and the treatment of osteoarthritis.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 12:08pm

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 11:30am

In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.

Key Points: 
  • In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

Thursday, October 14, 2021 - 9:00am

Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis.

Key Points: 
  • Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis.
  • BenevolentAI used its advanced molecular design capabilities to generate a potential best-in-class, oral, peripherally restricted candidate drug within two years of target validation.
  • The preclinical candidate has been experimentally validated in ex-vivo ulcerative colitis colon samples from patients who were unresponsive to the standard of care treatment.
  • Joanna Shields, Chief Executive Officer of BenevolentAI, commented, "Nominating a drug candidate for a novel ulcerative colitis target identified by our AI-drug discovery platform represents a milestone for BenevolentAI but more importantly, advances a new potential treatment for this debilitating disease."

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

Thursday, October 14, 2021 - 9:00am

LONDON, Oct. 14, 2021 /PRNewswire/ -- In a significant milestone for its (AI)-driven drug discovery platform, BenevolentAI has nominated a preclinical candidate for a novel ulcerative colitis target, and plans to advance the asset into clinical trials.

Key Points: 
  • Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis.
  • BenevolentAI used its advanced molecular design capabilities to generate a potential best-in-class, oral, peripherally restricted candidate drug within two years of target validation.
  • The preclinical candidate has been experimentally validated in ex-vivo ulcerative colitis colon samples from patients who were unresponsive to the standard of care treatment.
  • Joanna Shields, Chief Executive Officer of BenevolentAI, commented, "Nominating a drug candidate for a novel ulcerative colitis target identified by our AI-drug discovery platform represents a milestone for BenevolentAI but more importantly, advances a new potential treatment for this debilitating disease."

Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox

Thursday, October 14, 2021 - 6:45am

- Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.

Key Points: 
  • - Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.
  • The company said: "Topelia proposes to offer the ATT treatment alongside the current vaccination program to treat and vaccinate our way out of this pandemic.
  • The novel Antiviral Triple Therapy, to be branded as Ziverdox, comprises TGA-approved medications prescribed for decades with exceptional safety profiles.
  • Topelia Australia was founded based on the wealth of experience in commercialising the ground-breaking triple therapy cure for peptic ulcers which has saved over 18 thousand lives in Australia alone.

Athos Therapeutics Announces their Corporate Circle Membership to the Crohn's & Colitis Foundation and Participation in the "IBD Innovate" Conference

Wednesday, October 13, 2021 - 4:00pm

At the IBD INNOVATE: Product Development for Crohn's & Colitis conference ( https://www.crohnscolitisfoundation.org/ibd-innovate )Athos will be presenting exciting new data regarding its innovative platform to develop precision medicine therapeutics for IBD patients.

Key Points: 
  • At the IBD INNOVATE: Product Development for Crohn's & Colitis conference ( https://www.crohnscolitisfoundation.org/ibd-innovate )Athos will be presenting exciting new data regarding its innovative platform to develop precision medicine therapeutics for IBD patients.
  • The Company is developing precision therapeutics by the stratification of IBD patients into specific molecular subtypes.
  • "Our membership with the Crohn's & Colitis Foundation will enhance our collaborative efforts with the foundation, FDA, and other pharmaceutical companies to develop IBD precision therapeutics.
  • The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD).

Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies

Wednesday, October 13, 2021 - 12:30pm

Progenitys Oral Biotherapeutic Delivery System (OBDS), currently under development, is designed for systemic, needle-free delivery of biotherapeutics via an ingestible device.

Key Points: 
  • Progenitys Oral Biotherapeutic Delivery System (OBDS), currently under development, is designed for systemic, needle-free delivery of biotherapeutics via an ingestible device.
  • We believe we hold one of the most robust ingestible device patent portfolios, said Eric dEsparbes, interim CEO of Progenity.
  • The addition of these recent patents further strengthens our intellectual property position and underscores our commitment to innovation in advancing therapeutic discovery, development, and delivery.
  • Progenitys Drug Delivery System (DDS) is an ingestible capsule designed for targeted delivery of therapeutics to improve treatment of gastrointestinal disease.